Saimirra Innopharm Profile
Key Indicators
- Authorised Capital ₹ 19.25 Cr
as on 08-12-2024
- Paid Up Capital ₹ 16.00 Cr
as on 08-12-2024
- Company Age 24 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 180.36 Cr
as on 08-12-2024
- Satisfied Charges ₹ 80.87 Cr
as on 08-12-2024
- Revenue 4.49%
(FY 2022)
- Profit -50.64%
(FY 2022)
- Ebitda -2.61%
(FY 2022)
- Net Worth 6.07%
(FY 2022)
- Total Assets 17.08%
(FY 2022)
About Saimirra Innopharm
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 19.25 Cr and a paid-up capital of Rs 16.00 Cr.
The company currently has active open charges totaling ₹180.36 Cr. The company has closed loans amounting to ₹80.87 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Saimirra Innopharm Private Limited India is Anushree Chandak as COMPANY SECRETARY. Bernice Sugirtha, Shanmugam Muthusamy, Thanigainathan Thirumurugan, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232TN2000PTC044315
- Company No.
044315
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Mar 2000
- Date of AGM
11 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Saimirra Innopharm?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Anushree Chandak | Company Secretary | 09-Jan-2024 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shanmugam Muthusamy  | Director | 22-Oct-2012 | Current |
Bernice Sugirtha  | Director | 09-Jul-2024 | Current |
| Thanigainathan Thirumurugan | Director | 14-Jun-2013 | Current |
| Ayyavu Rajavel | Alternate Director | 22-Oct-2012 | Current |
| Jaganathan Jayaseelan | Director | 18-Jul-2012 | Current |
Financial Performance of Saimirra Innopharm.
Saimirra Innopharm Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 4.49% increase. The company also saw a substantial fall in profitability, with a 50.64% decrease in profit. The company's net worth moved up by a moderate rise of 6.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Saimirra Innopharm?
In 2023, Saimirra Innopharm had a promoter holding of 99.99%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Inventz Life Sciences Private LimitedActive 7 years 9 monthsJaganathan Jayaseelan is a mutual person
Delvin Surgicals Private LimitedActive 9 years 5 monthsAyyavu Rajavel and Jaganathan Jayaseelan are mutual person
Nuray Chemicals Private LimitedActive 12 years 7 monthsShanmugam Muthusamy, Ayyavu Rajavel and 1 more are mutual person
Scitus Pharma Services Private LimitedActive 7 years 3 monthsShanmugam Muthusamy and Ayyavu Rajavel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 May 2024 | ₹15.00 Cr | Open |
Hdfc Bank Limited Creation Date: 02 Feb 2024 | ₹3.62 M | Open |
Others Creation Date: 24 Feb 2023 | ₹165.00 Cr | Open |
How Many Employees Work at Saimirra Innopharm?
Saimirra Innopharm has a workforce of 154 employees as of Apr 24, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Saimirra Innopharm, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Saimirra Innopharm's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
